This suggests the possibility of using such synthetic PPARδ agonists as potential therapeutic agents for the treatment and/or prevention of obesity—however, due to the highly pleiotropic effect of PPARδ activation [105,115], their potential therapeutic use in humans still requires much research. Here, PPARD is linked to obesity due to melanocortin 4 receptor deficiency.